Sino Biopharmaceutical (01177.HK): Second-Generation Flurbiprofen Patch Approved for Marketing
NewTimeSpace News: On 6 August 2026, Sino Biopharmaceutical (01177.HK) announced that the second-generation flurbiprofen patch of its subsidiary Beijing Tide Pharmaceutical has been approved for launch by the NMPA. It is classified as a Class 5.1 new drug under national registration standards and granted a 4-year data protection period.
The announcement states that the second-generation flurbiprofen patch is indicated for osteoarthritis, periarthritis of shoulder, tendinitis and tenosynovitis, lateral humeral epicondylitis (tennis elbow), myalgia, as well as swelling and pain caused by trauma.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Sino Biopharmaceutical (01177.HK): TRD205 (AT2R Antagonist) Included in CDE’s Breakthrough Therapy Designation List
- ETF Financing Ranking | Guotai CSI All Share Investment Banking & Brokerage ETF (512880) had a net financing buy-in of CNY 60.09 million on Aug 5, ranked top among comparable funds
- Guotai CES Semiconductor Chip Industry ETF(512760) Rises 2.79%, Poised for 3 Consecutive Gains
